Fisher Asset Management LLC raised its stake in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) by 32.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,893 shares of the biopharmaceutical company’s stock after acquiring an additional 15,256 shares during the period. Fisher Asset Management LLC owned about 0.11% of Portola Pharmaceuticals worth $3,344,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in PTLA. Parametric Portfolio Associates LLC grew its position in Portola Pharmaceuticals by 50.4% in the first quarter. Parametric Portfolio Associates LLC now owns 32,145 shares of the biopharmaceutical company’s stock valued at $1,260,000 after acquiring an additional 10,776 shares during the period. Credit Agricole S A bought a new stake in shares of Portola Pharmaceuticals during the first quarter worth $196,000. Principal Financial Group Inc. grew its holdings in shares of Portola Pharmaceuticals by 0.3% during the first quarter. Principal Financial Group Inc. now owns 62,322 shares of the biopharmaceutical company’s stock worth $2,442,000 after purchasing an additional 202 shares during the last quarter. Teachers Advisors LLC grew its holdings in shares of Portola Pharmaceuticals by 225.5% during the first quarter. Teachers Advisors LLC now owns 259,325 shares of the biopharmaceutical company’s stock worth $10,163,000 after purchasing an additional 179,645 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its holdings in shares of Portola Pharmaceuticals by 4.0% during the first quarter. TIAA CREF Investment Management LLC now owns 223,924 shares of the biopharmaceutical company’s stock worth $8,776,000 after purchasing an additional 8,673 shares during the last quarter. Hedge funds and other institutional investors own 85.46% of the company’s stock.
Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) opened at 49.31 on Monday. Portola Pharmaceuticals, Inc. has a 12-month low of $15.68 and a 12-month high of $67.10. The company’s market cap is $2.84 billion. The company has a 50-day moving average price of $53.04 and a 200 day moving average price of $50.25.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.12). Portola Pharmaceuticals had a negative net margin of 807.93% and a negative return on equity of 145.12%. The company had revenue of $3.79 million during the quarter, compared to the consensus estimate of $4.28 million. During the same quarter last year, the firm posted ($1.02) EPS. The company’s quarterly revenue was down 10.4% on a year-over-year basis. On average, analysts forecast that Portola Pharmaceuticals, Inc. will post ($4.82) EPS for the current fiscal year.
Several brokerages have recently commented on PTLA. Credit Suisse Group set a $70.00 target price on Portola Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, August 10th. They noted that the move was a valuation call. BidaskClub cut Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Zacks Investment Research cut Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $80.00 target price on shares of Portola Pharmaceuticals in a report on Wednesday, September 6th. Finally, Morgan Stanley restated an “overweight” rating and set a $81.00 target price (up previously from $75.00) on shares of Portola Pharmaceuticals in a report on Friday, October 6th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Portola Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $65.15.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
What are top analysts saying about Portola Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Portola Pharmaceuticals Inc. and related companies.